These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39012619)

  • 1. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.
    Meertens M; Giraud EL; van der Kleij MBA; Westerdijk K; Guchelaar NAD; Bleckman RF; Rieborn A; Imholz ALT; Otten HM; Vulink A; Los M; Hamberg P; van der Graaf WTA; Gelderblom H; Moes DJAR; Broekman KE; Touw DJ; Koolen SLW; Mathijssen RHJ; Huitema ADR; van Erp NP; Desar IME; Steeghs N;
    Clin Pharmacokinet; 2024 Jul; 63(7):1045-1054. PubMed ID: 39012619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.
    Giraud EL; Westerdijk K; van der Kleij MBA; Guchelaar NAD; Meertens M; Bleckman RF; Rieborn A; Mohammadi M; Roets E; Mathijssen RHJ; Huitema ADR; Koolen SLW; Gelderblom H; Moes DJAR; Reyners AKL; Touw DJ; Keizer-Heldens P; Oosten AW; van der Graaf WTA; Steeghs N; van Erp NP; Desar IME;
    ESMO Open; 2024 Jun; 9(6):103477. PubMed ID: 38833964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
    de Wit D; van Erp NP; den Hartigh J; Wolterbeek R; den Hollander-van Deursen M; Labots M; Guchelaar HJ; Verheul HM; Gelderblom H
    Ther Drug Monit; 2015 Jun; 37(3):331-8. PubMed ID: 25271729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
    Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
    BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
    J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
    Tanaka H; Hiraga H; Takekuma Y; Harabayashi T; Nagamori S; Endo M; Sugawara M
    Biol Pharm Bull; 2020 May; 43(5):762-766. PubMed ID: 32115446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
    Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
    Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
    Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
    Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
    Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
    J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.
    Vlenterie M; Oyen WJ; Steeghs N; Desar IME; Verheijen RB; Koenen AM; Grootjans W; DE Geus-Oei LF; VAN Erp NP; VAN DER Graaf WT
    Anticancer Res; 2019 Mar; 39(3):1309-1316. PubMed ID: 30842163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.
    Verheijen RB; Bins S; Mathijssen RH; Lolkema MP; van Doorn L; Schellens JH; Beijnen JH; Langenberg MH; Huitema AD; Steeghs N;
    Clin Cancer Res; 2016 Dec; 22(23):5738-5746. PubMed ID: 27470967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A; Koch A; Grünwald V
    Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib.
    Fukudo M; Tamaki G; Azumi M; Shibata H; Tandai S
    Br J Clin Pharmacol; 2021 Apr; 87(4):2132-2139. PubMed ID: 33010046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
    Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
    J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.